Literature DB >> 25362710

Systematic review of treatments for psoriatic arthritis: 2014 update for the GRAPPA.

Laura C Coates1, Arthur Kavanaugh2, Christopher T Ritchlin2.   

Abstract

Psoriatic arthritis (PsA) is a chronic systemic inflammatory disorder characterized by the association of arthritis and periarticular inflammation in patients with psoriasis. In addition to a heterogeneous and variable clinical course, PsA is complex and multifaceted and may include prominent involvement in the peripheral and axial diarthrodial joints, the skin and nails, and in periarticular structures such as entheses. Simultaneous inflammation in the skin and musculoskeletal structures in a single patient, a relatively common scenario, often leads to marked decrease in function and quality of life. Thus, it is essential for the clinician to document the extent of disease involvement and craft a therapeutic plan that addresses the different domains of disease. In an effort to update previous treatment recommendations developed by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), several evidence-based, systemic reviews of therapies for PsA were completed, analyzed, and circulated for consensus.

Entities:  

Keywords:  AXIAL DISEASE; DACTYLITIS; ENTHESITIS; NAIL PSORIASIS; PERIPHERAL ARTHRITIS; PSORIASIS

Mesh:

Substances:

Year:  2014        PMID: 25362710     DOI: 10.3899/jrheum.140875

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

Review 1.  Entheseal involvement in systemic disorders.

Authors:  Gleb Slobodin; Doron Rimar; Nina Boulman; Lisa Kaly; Michael Rozenbaum; Itzhak Rosner; Majed Odeh
Journal:  Clin Rheumatol       Date:  2015-09-10       Impact factor: 2.980

2.  Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review.

Authors:  Lucia Sara D'Angiolella; Paolo Angelo Cortesi; Alessandra Lafranconi; Mariangela Micale; Sveva Mangano; Giancarlo Cesana; Lorenzo Giovanni Mantovani
Journal:  Pharmacoeconomics       Date:  2018-05       Impact factor: 4.981

3.  Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE.

Authors:  Maria Antonietta D'Agostino; Georg Schett; Alejandra López-Rdz; Ladislav Šenolt; Katalin Fazekas; Ruben Burgos-Vargas; Jose Maldonado-Cocco; Esperanza Naredo; Philippe Carron; Anne-Marie Duggan; Punit Goyanka; Maarten Boers; Corine Gaillez
Journal:  Rheumatology (Oxford)       Date:  2022-05-05       Impact factor: 7.046

Review 4.  Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations.

Authors:  Laure Gossec; Laura C Coates; Maarten de Wit; Arthur Kavanaugh; Sofia Ramiro; Philip J Mease; Christopher T Ritchlin; Désirée van der Heijde; Josef S Smolen
Journal:  Nat Rev Rheumatol       Date:  2016-11-10       Impact factor: 20.543

5.  Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study.

Authors:  Ennio Lubrano; Andrea Delle Sedie; Marco Romanelli; Maria Sole Chimenti; Luca Bianchi; Stefano Piaserico; Catia De Felice; Dario Graceffa; Maria Ilenia De Andres; Salvatore Curatolo; Rosa Daniela Grembiale; Stefano Dastoli; Chiara Arcuri; Rosa Giuseppa Angileri; Francesca Prignano; Francesca Bandinelli; Elena Baldissera; Santo Raffaele Mercuri; Chiara Franchi; Matteo Longhi; Angela Patrì; Francesco Caso; Giuseppe Passiu; Maria Antonia Montesu; Simone Parisi; Elena Stroppiana; Genoveffa Scotto di Luzio; Giovanni Italiano; Sergio Di Nuzzo; Daniele Santilli; Laura Bigi; Federica Lumetti; Concetto Paolo Agnusdei; Maria Grazia Ferrucci; Giuliana Gualberti; Francesca Marando; Roberta Ramonda; Francesco Cusano
Journal:  Clin Rheumatol       Date:  2020-11-06       Impact factor: 2.980

6.  Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US.

Authors:  Vibeke Strand; Elaine Husni; Jenny Griffith; Zheng-Yi Zhou; James Signorovitch; Arijit Ganguli
Journal:  Rheumatol Ther       Date:  2016-09-15

7.  Patients' Attitudes and Experiences of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Synthesis.

Authors:  Ayano Kelly; Kathleen Tymms; David J Tunnicliffe; Daniel Sumpton; Chandima Perera; Kieran Fallon; Jonathan C Craig; Walter Abhayaratna; Allison Tong
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-03-24       Impact factor: 4.794

8.  Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis.

Authors:  Vibeke Strand; M Elaine Husni; Keith A Betts; Yan Song; Rakesh Singh; Jenny Griffith; Marci Beppu; Jing Zhao; Arijit Ganguli
Journal:  BMC Rheumatol       Date:  2018-02-12

9.  TWEAK-binding autoantibodies are generated during psoriatic arthritis and are not influenced by anti-TNF therapy.

Authors:  Sandrine Guis; Philippe Berbis; Delphine Stephan; Daniel Bertin; Florent Amatore; Nathalie Balandraud; Nathalie Lesavre; Sophie Desplat-Jégo
Journal:  J Transl Med       Date:  2016-06-23       Impact factor: 5.531

Review 10.  Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic review.

Authors:  Gabrielle H Kingsley; David L Scott
Journal:  Psoriasis (Auckl)       Date:  2015-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.